Nancy T. Sklarin
- Oncology top 2%
- Radiology, Nuclear Medicine and Imaging top 2%
- Molecular Biology top 10%
- Cancer Research top 5%
- Pulmonary and Respiratory Medicine top 5%
- Co-authors
- Andrew D. SeidmanLarry NortonClifford A. HudisJosé BaselgaI. Craig HendersonJ. MooreDebu TripathyPaul Peter Rosen
- Topics
- Cancer Treatment and Pharmacology (15 papers)HER2/EGFR in Cancer Research (14 papers)Breast Cancer Treatment Studies (6 papers)
- Partner nations
- United StatesBelgiumUnited Kingdom
In The Last Decade
Nancy T. Sklarin
36 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 1.6k
- Radiology, Nuclear Medicine and Imaging 784
- Molecular Biology 783
- Cancer Research 418
- Pulmonary and Respiratory Medicine 397
Countries citing papers authored by Nancy T. Sklarin
This map shows the geographic impact of Nancy T. Sklarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy T. Sklarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy T. Sklarin more than expected).
Fields of papers citing papers by Nancy T. Sklarin
This network shows the impact of papers produced by Nancy T. Sklarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy T. Sklarin. The network helps show where Nancy T. Sklarin may publish in the future.
Co-authorship network of co-authors of Nancy T. Sklarin
This figure shows the co-authorship network connecting the top 25 collaborators of Nancy T. Sklarin. A scholar is included among the top collaborators of Nancy T. Sklarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy T. Sklarin. Nancy T. Sklarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 26 | |
| 3 | 39 | |
| 4 | 18 | |
| 5 | 4 | |
| 6 | 75 | |
| 7 | 50 | |
| 8 | 2 | |
| 9 | 4 | |
| 10 | 3 | |
| 11 | 9 | |
| 12 | 11 | |
| 13 | 184 | |
| 14 | Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. | 229 |
| 15 | 9 | |
| 16 | 5 | |
| 17 | 9 | |
| 18 | Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.breakdown → | 1088 |
| 19 | 69 | |
| 20 | 19 |
About Nancy T. Sklarin
Nancy T. Sklarin is a scholar working on Oncology, Dermatology and Cancer Research, having authored 36 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (14 papers) and Breast Cancer Treatment Studies (6 papers). The work is most often cited by research in Oncology (1.6k citations), Radiology, Nuclear Medicine and Imaging (784 citations) and Cancer Research (418 citations). Nancy T. Sklarin has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Andrew D. Seidman, Larry Norton, Clifford A. Hudis, José Baselga, I. Craig Henderson, J. Moore, Debu Tripathy, Paul Peter Rosen, Sharon A. Baughman and Christopher C. Benz. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.